Trial
NCT01465386
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Intervention
bortezomib
Why stopped
Closed early due to slow enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-04